That test could help identify patients at greatest risk for potentially deadly cardiac problems such as coronary artery disease, atrial fibrillation (irregular heartbeat) and heart failure, and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.

Trinity Health Muskegon has successfully implanted a new FDA-approved pacemaker that is offering hope for those with abnormal heart rhythms.